IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction.

A nonsignificant trend favoring UST in the clinical response rate (52% vs. 25%, p < 0.24) and the clinical remission rate (25% vs. 27%, p < 0.82) was observed, as expected, in the subgroup of anti-TNFα–experienced patients [ 22 ].

also in 5,406 other papers